COMMUNIQUÉS West-GlobeNewswire
-
RQ Bio Announces $115 Million (£85.5 Million) Series A Financing to Advance Long-Acting Antibody Programme RQB01 for Full Season Influenza Prevention
24/06/2026 -
FEATOL Introduces Anti-Fatigue Mat Designed to Improve Comfort During Long Hours of Standing
24/06/2026 -
uniQure Announces Pricing of Upsized $225 Million Public Offering
24/06/2026 -
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
24/06/2026 -
Glass House Brands Provides Notice of Warrant Acceleration
24/06/2026 -
TWL Announces Expanded Online Access to GLP-1 Weight-Loss Care With Insurance and Self-Pay Options
24/06/2026 -
Nyxoah to Host Investor Day in New York on July 8, 2026
23/06/2026 -
Acquisition of Own Shares
23/06/2026 -
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
23/06/2026 -
Zealthy Expands Online Access to Ozempic Evaluations and Insurance Support for Eligible Patients With Type 2 Diabetes
23/06/2026 -
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index
23/06/2026 -
Nyxoah Organisera une Journée Investisseurs à New York le 8 juillet 2026
23/06/2026 -
MSK Masters Announces Release of Sonography of the Extremities - Techniques and Protocols, 5th Edition
23/06/2026 -
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
23/06/2026 -
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
23/06/2026 -
DBV Technologies intégrera l’Indice Euronext Tech Leaders
23/06/2026 -
Zealthy Launches Dedicated Tirzepatide Care Pathway for Weight-Management Patients
23/06/2026 -
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
23/06/2026 -
FitRx Expands Online Weight-Management Program With Needle-Free Oral Semaglutide Option
23/06/2026
Pages